The Hetero Ring Has Exactly 13 Ring Carbons (e.g., Erythromycin, Etc.) Patents (Class 514/29)
  • Patent number: 12005071
    Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.
    Type: Grant
    Filed: March 20, 2023
    Date of Patent: June 11, 2024
    Assignee: Dechra Veterinary Products, LLC
    Inventors: Neil E. Paulsen, Gail L. Dempsey, Michael S. Daniel, Tiffany G. Tomlinson, Douglas I. Hepler, Raymond Petzold
  • Patent number: 11980627
    Abstract: There are disclosed therapies and preventions of prion protein complex infections. The transcription of the amyloid precursor protein gene and PrP gene and the RNA transcript are the rate-limiting steps and are most susceptible for blockage and control of the process of amyloid protein formation and PrPsc formation. Thus, therapies and prevention regimes for prion protein complex infections interrupt this process at the level of DNA transcription to RNA, RNA transport to the mitochondrion for protein synthesis and deposition in the cerebral cortex neurons.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: May 14, 2024
    Inventor: Joshua O. Atiba
  • Patent number: 11884984
    Abstract: Provided herein are kits and methods for detecting, monitoring, and classifying a nongonococcal urethritis (NGU) infection in a male subject based on a genitourinary microbiome of a subject, as well as related methods of treating. Also provided are kits and methods for classifying a risk of human immunodeficiency virus (HIV) infection in a subject based on a genitourinary microbiome of a subject, as well as related methods of preventing infection.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: January 30, 2024
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Sujatha Srinivasan, David N. Fredricks
  • Patent number: 11786541
    Abstract: Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed. The disclosed compositions are useful for treating, preventing, or reducing the spread of infections by filovirus. A method includes administering at least one agent of the present disclosure to an individual infected with or exposed to a filovirus, wherein the step of administering is carried out for a suitable time period so that the individual is treated; and determining whether the individual has been treated, wherein the step of determining includes one of measuring an inhibition in viral replication, measuring a decrease in viral load, or reducing at least one symptom associated with the filovirus.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: October 17, 2023
    Assignee: RedHill Biopharma Ltd.
    Inventors: Reza Fathi, Dror Ben-Asher, Guy Goldberg
  • Patent number: 11781191
    Abstract: Oligonucleotides for use in amplifying at least one gene present in M. riyadhense are disclosed. The oligoncleotides include forward primers, SEQ ID NO:1, 3, 5, and 7 and the reverse primers comprises, consists essentially of or consists of SEQ ID NO:2, 4, 6, and 8, fragment(s), derivative(s), mutation(s), or complementary sequence(s) thereof. Also provided are methods for detecting the presence of M. riyadhense in a sample. The method includes contacting a biological sample with a pair of forward/reverse primers, under conditions suitable for amplification of at least one gene product from M. riyadhense if present in a sample and detecting the presence of the amplification product. The oligonucleotides and method disclosed herein can be used to determine the presence of M. riyadhense in a biological or non-biological sample. The sample can be obtained from a subject such as a human subject.
    Type: Grant
    Filed: August 8, 2020
    Date of Patent: October 10, 2023
    Assignee: KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Arnab Pain, Qingtian Guan
  • Patent number: 11628180
    Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: April 18, 2023
    Assignee: Dechra Veterinary Products, LLC
    Inventors: Neil E. Paulsen, Gail L. Dempsey, Michael S. Daniel, Tiffany G. Tomlinson, Douglas I. Hepler, Raymond Petzold
  • Patent number: 11466046
    Abstract: Provided herein are methods of preparing new 14-membered ketolides via coupling of an eastern and western half moiety, followed by macrocyclization, and optional functionalization. Intermediates in the synthesis of these ketolides including the eastern and western halves are also provided. Pharmaceutical compositions and methods of treating infectious diseases and inflammatory conditions using these ketolides are also provided.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: October 11, 2022
    Assignee: President and Fellows of Harvard College
    Inventors: Andrew G. Myers, Ian Bass Seiple, Ziyang Zhang
  • Patent number: 11331269
    Abstract: It has been discovered that lung tumor growth is associated with a dysregulation of the local microbiota, including an increased total bacterial load and reduced bacterial diversity in the airway. In the lungs, commensal bacteria, which are otherwise non-pathogenic and colonize pulmonary tissue at a much lower density in healthy individuals, provoke chronic inflammation and exacerbation of lung cancer through tumor-infiltrating immune cells. Thus, targeting the lung microbiota and its responding immune pathways is useful in treating lung cancer. Disclosed are compositions and methods targeting the lung microbiota and its responding immune pathways in a subject by specific targeting of commensal bacteria in the subject. Typically, the methods involve administering an effective amount of one or more therapeutics such as an antibiotic that reduces the local bacterial load, blocks or depletes tumor-infiltrating immune cells, and/or locally inhibits one or more cytokines or chemokines.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: May 17, 2022
    Assignees: Massachusetts Institute of Technology, The Broad Institute, Inc.
    Inventors: Chengcheng Jin, Georgia Lagoudas, Paul Blainey, Tyler Jacks
  • Patent number: 11324220
    Abstract: This invention relates to processes for the preparation of antiparasitic isoxazoline compounds enriched in an enantiomer using quinine-based chiral phase transfer catalyst. The invention also relates to novel quinine-based phase transfer catalysts and to a toluene solvent form of the isoxazoline compound of the invention.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: May 10, 2022
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventor: Chunhua Yang
  • Patent number: 11236120
    Abstract: The invention provides novel compounds that are derivatives of Azithromycin and that have been found by the current inventors to have low antimicrobial activity but significant epithelial barrier enhancement properties. The invention further provides use of the compounds as a medicament, in particular in the treatment or prophylaxis of a disease or condition that is caused by a defect in epithelial cells or tissue, or a disease or condition that benefits from enhancement or restoration of epithelial barrier function, for example diseases of the respiratory tract.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: February 1, 2022
    Assignee: EPIENDO PHARMACEUTICALS EHF
    Inventors: Fridrik Runar Gardarsson, Fredrik Lehmann, Peter Teodorovic
  • Patent number: 11160821
    Abstract: Antibiotics having intrinsic anti-mitochondrial properties may be chemically modified to target the antibiotics to mitochondria, and the resulting “antimitoscins” may have enhanced anti-cancer properties, among other advantageous properties. Also described are methods for identifying antimitoscins, methods of using antimitoscins to target cancer stem cells, and pharmaceutical compositions for treating cancer containing one or more antimitoscins as the active ingredient. Specific antimitoscins compounds and groups of antimitoscins are also disclosed.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: November 2, 2021
    Assignee: LUNELLA BIOTECH, INC.
    Inventors: Michael P. Lisanti, Federica Sotgia
  • Patent number: 11090325
    Abstract: Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed. The disclosed compositions are useful for treating, reventing, or reducing the spread of infections by filovirus. A method includes administering at least one agent of the present disclosure to an individual infected with or exposed to a filovirus, wherein the step of administering is carried out for a suitable time period so that the individual is treated; and determining whether the individual has been treated, wherein the step of determining includes one of measuring an inhibition in viral replication, measuring a decrease in viral load, or reducing at least one symptom associated with the filovirus.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: August 17, 2021
    Assignee: RedHill Biopharma Ltd.
    Inventors: Reza Fathi, Dror Ben-Asher, Guy Goldberg
  • Patent number: 11072575
    Abstract: A method of preparing a compound of formula (I): is disclosed. The compound of formula (I) can be used as an antioxidant agent. The compound can also be used as an antibacterial agent to inhibit Staphylococcus aureus 18-596 and Staphylococcus aureus 18-596.
    Type: Grant
    Filed: September 19, 2020
    Date of Patent: July 27, 2021
    Assignee: XI'AN TAIKOMED PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Yonghong Tang, Minghui Chang, Huafeng Qi, Peiyu Zhou, Zhuanmei Yuan, Wenbo Yao, Guaiping Qiao, Bin Tian, Juan Li
  • Patent number: 11045486
    Abstract: Provided are a therapeutic agent and a therapeutic method for canine atopic dermatitis. The therapeutic method for atopic dermatitis in animals and the therapeutic drug for atopic dermatitis in animals are characterized in that 2.5-10.0 mg/kg of roxithromycin and/or a pharmaceutically acceptable salt thereof and 12.5-50.0 mg/kg of pentoxifylline and/or a pharmaceutically acceptable salt thereof are to be simultaneously administered along with meals at 12-hour intervals for 60 days. The present invention provides an advantageous effect of preventing recurrence of symptoms for at least 30 days even after cessation of drug administration.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: June 29, 2021
    Inventor: Yoshihiko Fujimoto
  • Patent number: 11013678
    Abstract: A skin care product is provided. The skin care product includes a multi-component skin care composition disposed in a multi-chamber container. The multi-component skin care composition includes an aqueous carrier component and a nicotinamide riboside component disposed in separate chambers, which prevents these components from contacting one another prior to use. The aqueous carrier component and the nicotinamide riboside component can be separated from one another by one or more fluid impermeable dividing members and/or activatable elements, which upon activation enable contact between the aqueous carrier component and nicotinamide riboside component.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: May 25, 2021
    Assignee: The Procter & Gamble Company
    Inventors: Tomohiro Hakozaki, John Erich Oblong, Jesus Velazquez
  • Patent number: 10729709
    Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: August 4, 2020
    Assignee: Piedmont Animal Health Inc.
    Inventors: Neil E. Paulsen, Gail L. Dempsey, Michael S. Daniel, Tiffany G. Tomlinson, Douglas Hepler, Raymond Petzold
  • Patent number: 10725039
    Abstract: The present invention relates to methods for the diagnosing, prognosing, monitoring, differentiating, treating, and managing of Lyme disease in a subject. The methods according to the invention are characterized by the detection of a biomarker signature comprised of a combination of two or more analytes indicative of disease.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: July 28, 2020
    Assignee: VERAMARX, INC.
    Inventors: Whitney Richards, Floyd E. Taub, Robert A. Rubin
  • Patent number: 10723752
    Abstract: The invention provides novel compounds that are derivatives of Azithromycin and that have been found by the current inventors to have low antimicrobial activity but significant epithelial barrier enhancement properties. The invention further provides use of the compounds as a medicament, in particular in the treatment or prophylaxis of a disease or condition that is caused by a defect in epithelial cells or tissue, or a disease or condition that benefits from enhancement or restoration of epithelial barrier function, for example diseases of the respiratory tract.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: July 28, 2020
    Assignee: EPIENDO PHARMACEUTICALS EHF
    Inventors: Fridrik Runar Gardarsson, Fredrik Lehmann, Peter Teodorovic
  • Patent number: 10633407
    Abstract: Provided herein are methods of preparing new 14-membered ketolides via coupling of an eastern and western half moiety, followed by macro-cyclization, and optional functionalization. Intermediates in the synthesis of these ketolides including the eastern and western halves are also provided. Pharmaceutical compositions and methods of treating infectious diseases and inflammatory conditions using these ketolides are also provided.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: April 28, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Andrew G. Myers, Ian Bass Seiple, Ziyang Zhang
  • Patent number: 10543222
    Abstract: Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed. The disclosed compositions are useful for treating, reventing, or reducing the spread of infections by filovirus. A method includes administering at least one agent of the present disclosure to an individual infected with or exposed to a filovirus, wherein the step of administering is carried out for a suitable time period so that the individual is treated; and determining whether the individual has been treated, wherein the step of determining includes one of measuring an inhibition in viral replication, measuring a decrease in viral load, or reducing at least one symptom associated with the filovirus.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: January 28, 2020
    Assignee: RedHill Biopharma Ltd.
    Inventors: Reza Fathi, Dror Ben-Asher, Guy Goldberg
  • Patent number: 10500223
    Abstract: The present invention provides a therapeutic agent for myotonic dystrophy which inhibits aberrant splicing responsible for myotonic dystrophy, resulting in an increase in a normally spliced product and thus improvement in a symptom of myotonic dystrophy, and is highly safe for use in long-term administration. The therapeutic agent for myotonic dystrophy comprises, as an active ingredient, at least one compound selected from the group consisting of erythromycin, clarithromycin and azithromycin, a pharmaceutically acceptable salt or hydrate thereof, or a prodrug thereof.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: December 10, 2019
    Assignee: Osaka University
    Inventors: Masayuki Nakamori, Hideki Mochizuki
  • Patent number: 10406203
    Abstract: An ophthalmic treatment composition for the treatment of dry eye consists essentially of squalane in an amount by weight of 1% to 100%; and mineral oil in an amount by weight of 0% to 99%. Preferably, the mineral oil is a light mineral oil or mixture of light mineral oils and is present in an amount by weight of 1% to 10%. The composition is effectively devoid of water, preservatives, emulsifiers and dispersing agents. A related ophthalmic treatment composition comprises squalane in an amount by weight of 1% to 99% and mineral oil in an amount by weight of 0% to 99% and at least one hydrophobic or lipophilic pharmaceutical substance in an amount by weight of 0.01% to 5%, effective for treatment of at least one ophthalmic condition.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: September 10, 2019
    Inventor: Paul Gavaris
  • Patent number: 10350226
    Abstract: There are disclosed therapies and preventions of prion protein complex infections. The transcription of the amyloid precursor protein gene and PrP gene and the RNA transcript are the rate-limiting steps and are most susceptible for blockage and control of the process of amyloid protein formation and PrPsc formation. Thus, therapies and prevention regimes for prion protein complex infections interrupt this process at the level of DNA transcription to RNA, RNA transport to the mitochondrion for protein synthesis and deposition in the cerebral cortex neurons.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: July 16, 2019
    Inventor: Joshua O. Atiba
  • Patent number: 10293078
    Abstract: A polymerizable polymethylmethacrylate bone cement, in which the initial viscosity of the cement dough can be controlled. The polymerizable bone cement composition comprises a monomer for radical polymerization, a powdered polymethylmethacrylate-co-polymer soluble in the monomer or a mixture comprising polymethylmethacrylate-co-polymers, a polymerization initiator, and a radiopaquer, wherein the powdered polymethylmethacrylate-co-polymer comprises at least one particulate polymethylmethacrylate-co-polymer having a molar mass of more than or equal to 200,000 g/mol, and the polymethylmethacrylate-co-polymer is obtainable by polymerization of a mixture of 90.0% or more by weight methylmethacrylate and 10.0% or less by weight of one or more comonomers, wherein the weight ratio of component A comprising the polymethylmethacrylate-co-polymer, radiopaquer, and polymerization initiator, and component B comprising a monomer for radical polymerization, stabilizer, and polymerization accelerator, is approximately 2.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: May 21, 2019
    Assignee: HERAEUS MEDICAL GMBH
    Inventors: Sebastian Vogt, Thomas Kluge
  • Patent number: 10286035
    Abstract: An ophthalmic treatment composition for the treatment of dry eye consists essentially of squalane in an amount by weight of 1% to 100%; and mineral oil in an amount by weight of 0% to 99%. Preferably, the mineral oil is a light mineral oil or mixture of light mineral oils and is present in an amount by weight of 1% to 10%. The composition is effectively devoid of water, preservatives, emulsifiers and dispersing agents. A related ophthalmic treatment composition comprises squalane in an amount by weight of 1% to 99% and mineral oil in an amount by weight of 0% to 99% and at least one hydrophobic or lipophilic pharmaceutical substance in an amount by weight of 0.01% to 5%, effective for treatment of at least one ophthalmic condition.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: May 14, 2019
    Inventor: Paul Gavaris
  • Patent number: 10286003
    Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: May 14, 2019
    Assignee: Piedmont Animal Health, LLC
    Inventors: Neil E. Paulsen, Gail L. Dempsey, Michael S. Daniel, Tiffany G. Tomlinson, Douglas Hepler, Raymond Petzold
  • Patent number: 10221206
    Abstract: The application relates to the macrolide compound of the formula (I): wherein * indicates a stereocentre which is in (R) or (S) configuration, or a pharmaceutically acceptable salt or ester thereof.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: March 5, 2019
    Assignee: Basilea Pharmaceutica AG
    Inventors: Johannes Laurenz Kellenberger, Jürg Dreier
  • Patent number: 10201548
    Abstract: A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: February 12, 2019
    Assignee: SUN PHARMA GLOBAL FZE
    Inventors: Lyle Bowman, Kamran Hosseini
  • Patent number: 9974800
    Abstract: Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed. The disclosed compositions are useful for treating, reventing, or reducing the spread of infections by filovirus. A method includes administering at least one agent of the present disclosure to an individual infected with or exposed to a filovirus, wherein the step of administering is carried out for a suitable time period so that the individual is treated; and determining whether the individual has been treated, wherein the step of determining includes one of measuring an inhibition in viral replication, measuring a decrease in viral load, or reducing at least one symptom associated with the filovirus.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: May 22, 2018
    Assignee: RedHill Biopharma Ltd.
    Inventors: Reza Fathi, Dror Ben-Asher, Guy Goldberg
  • Patent number: 9944740
    Abstract: Disclosed herein are polymers made from at least one monomer of formulae (I), (II), (III), and (IV), in combination with a monomer of formula (V) that may be used in pharmaceutical formulations. These polymers comprise a hydrocarbon backbone and are made from monomers that contain at least one carbon-carbon double bond. Methods of making these polymers are also disclosed.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: April 17, 2018
    Assignee: Regents of the University of Minnesota
    Inventors: Tushar S. Navale, Jeffrey M. Ting, Frank S. Bates, Theresa M. Reineke
  • Patent number: 9861616
    Abstract: Compounds of formula (I), compositions comprising them, and methods and uses thereof are described herein for the treatment of respiratory diseases, including cystic fibrosis. Inhalation formulations of macrolide antibiotics are also described herein. The treatment of bacterial infections continues to be an important endeavor of pharmaceutical research and development. The specter of bacterial resistance to currently available antibiotics is ever-present, and accordingly, new and improved compounds, pharmaceuticals formulations, treatment methods, and treatment protocols are needed.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 9, 2018
    Assignee: CEMPRA PHARMACEUTICALS, INC.
    Inventor: Prabhavathi Fernandes
  • Patent number: 9815863
    Abstract: The invention described herein pertains to a novel macrolide antibacterial agent of formula (I): A-L-Q, as defined herein, and pharmaceutically acceptable salts, solvates, and hydrates thereof. Inter alia, the new macrolide antibacterial agent is active against a number of bacterial species, including resistant species.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: November 14, 2017
    Assignee: CEMPRA PHARMACEUTICALS, INC.
    Inventor: David E. Pereira
  • Patent number: 9700509
    Abstract: The present invention relates to a solution containing at least one water-miscible biocompatible solvent and a lipophilic substance dissolved therein, wherein upon contact with aqueous body fluid the dissolved lipophilic substance is precipitated out of the solution in the form of nanoparticles and a nanosuspension is formed.
    Type: Grant
    Filed: November 27, 2009
    Date of Patent: July 11, 2017
    Assignee: UNIVERSITÄT REGENSBURG
    Inventors: Achim Göpferich, Christoph Luschmann
  • Patent number: 9650395
    Abstract: The present description relates to compounds and forms and pharmaceutical compositions thereof and methods for use thereof to treat or ameliorate bacterial infections caused by wild-type and multi-drug resistant Gram-negative and Gram-positive pathogens.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: May 16, 2017
    Assignee: PTC Therapeutics, Inc.
    Inventors: Arthur Branstrom, Vara Prasad Venkata Nagendra Josyula, Michael Andrew Arnold, Aleksey I. Gerasyuto, Gary Karp, Jiashi Wang, Tamil Arasu, John David Baird, Wu Du, Olya Ginzburg, Yi Jin Kim Gorske, Jana Narasimhan, Srinivasa Peddi, Hongyan Qi, Sean Wesley Smith, Anthony Allan Turpoff, Richard Gerald Wilde, Tianle Yang, Nanjing Zhang, Xiaoyan Zhang
  • Patent number: 9453042
    Abstract: Described herein are processes for the preparation of compounds of formula (I): and pharmaceutically acceptable salts, solvates, and hydrates thereof.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: September 27, 2016
    Assignee: CEMPRA PHARMACEUTICALS, INC.
    Inventors: David E. Pereira, Manish Kanchanbhai Patel, Keshav Deo
  • Patent number: 9427468
    Abstract: The present invention includes compositions and methods for diagnosing and treating CA-MRSA infections in patients. The methods are based on the finding that combining cefoxitin and a synthetic penicillin in a treatment regimen results in a synergistic effect of the two drugs, an effect that is related to PBP4 activity in CA-MRSA isolates. Also provided is a CA-MRSA-specific biomarker which can be used to detect the presence of a CA-MRSA infection in a patient.
    Type: Grant
    Filed: August 7, 2008
    Date of Patent: August 30, 2016
    Assignee: TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Ambrose Cheung, Guido Memmi
  • Patent number: 9409940
    Abstract: Disclosed herein is a method or process for preparing erythromycin thiocyanate, which belongs to the pharmaceutical field. Also disclosed herein is a method of using erythromycin or a salt thereof as a raw material, which can be dissolved in acetone or a mixed solvent containing acetone to yield erythromycin thiocyanate A as the main component and low in the content of impurities. Said erythromycin thiocyanate could be used as the raw material for preparing Azithromycin and Clarithromycin, which meets the standards made by European Union and US.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: August 9, 2016
    Assignee: HEC PHARM CO., LTD.
    Inventors: Hui Xiong, Keyi Zhao, Zhaozheng Deng
  • Patent number: 9409905
    Abstract: The present description relates to compounds and forms and pharmaceutical compositions thereof and methods for use thereof to treat or ameliorate bacterial infections caused by wild-type and multi-drug resistant Gram-negative and Gram-positive pathogens.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: August 9, 2016
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Arthur Branstrom, Vara Prasad Venkata Nagendra Josyula, Michael Andrew Arnold, Aleksey I. Gerasyuto, Gary Karp, Jiashi Wang, John David Baird, Guangming Chen, Olya Ginzburg, Jana Narasimhan, Srinivasa Peddi, Hongyan Qi, Sean Wesley Smith, Matthew G. Woll, Tianle Yang, Nanjing Zhang, Xiaoyan Zhang
  • Patent number: 9351987
    Abstract: The present invention further relates to ivermectin, most preferably formulated as an implant for administration of pet and domestic animals. These formulations provide long term protection against Dirofilaria parasites, without the risks for secondary adverse events of conventional formulations. Preferred formulations are implants and are administered at least twice a year, once a year, or at least once in 18 months, up to 24 months.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: May 31, 2016
    Assignee: CEVA SANTE ANIMALE
    Inventors: Patrick Forget, Vassilios Kaltsatos, Stephan Warin
  • Patent number: 9206214
    Abstract: The inventions discloses a process for preparation of compounds of Formula (IX), Wherein, R is C1-C6 alkyl, R1 is hydrogen or a hydroxyl protecting group, and R2 is hydrogen or fluorine.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: December 8, 2015
    Assignee: Wockhardt Ltd.
    Inventors: Vijaykumar Jagdishwar Patil, Satish Birajdar, Bharat Dond, Bharat Kalidas Trivedi
  • Patent number: 9156855
    Abstract: The present invention relates generally to methods and compounds for regulating the release of nitric oxide in the vicinity of biofilm-forming microorganisms to regulate programmed cell death in the microorganisms and thereby promote dispersal of microorganism from biofilms and/or inhibit biofilm formation or development. More particularly, the invention relates to the use of compounds to provide spatial and temporal control over nitric oxide release.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: October 13, 2015
    Assignees: Newsouth Innovation Pty Limited, University of Wollongong
    Inventors: Nicolas Barraud, Bharat Gangadhar Kardak, Michael John Kelso, Staffan Kjelleberg, Scott Rice
  • Patent number: 9155716
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 13, 2015
    Assignee: Allergan, Inc.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • Patent number: 9145436
    Abstract: The invention provides novel compounds and compositions and methods for making and using the compounds and compositions.
    Type: Grant
    Filed: October 10, 2011
    Date of Patent: September 29, 2015
    Inventors: Michael W. Burnet, Jan-Hinrich Guse, Christiane Bauerlein, Mary Eggers
  • Patent number: 9126995
    Abstract: There is provided a method for catalytic asymmetric synthesis of optically active isoxazoline compound and an optically active isoxazoline compound. A method for catalytic asymmetric synthesis of optically active isoxazoline compound of a formula (6) including reacting an ?,?-unsaturated carbonyl compound of a formula (1) and a hydroxylamine in a solvent in the presence of a base by adding a chiral phase transfer catalyst. An optically active isoxazoline compound of a formula (13) that can be synthesized by the method.
    Type: Grant
    Filed: November 8, 2012
    Date of Patent: September 8, 2015
    Assignee: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Ken-ichi Toyama, Yuji Moriyama, Kazutaka Matoba, Manabu Yaosaka, Eitatsu Ikeda
  • Publication number: 20150141328
    Abstract: Disclosed herein are systems and methods for stimulating meibomian gland epithelial cell function by administering to the ocular surface or immediate vicinity of an eye of a subject an effective amount of a pharmaceutical composition containing a PLD-inducing compound, such as the cationic amphiphilic drugs (e.g. azithromycin), androgen or an androgen analogue with androgen effectiveness, corticosteroid, progesterone, IGF-1 or an IGF-1 analogue (e.g. insulin), GH, and mixtures thereof. The pharmaceutical compositions are effective to treat a variety of aliments to the eye including meibomian gland dysfunction, evaporative dry eye disease, lipid abnormalities in meibum or the tear film, and autoimmune diseases such as Sjögren's syndrome.
    Type: Application
    Filed: November 18, 2014
    Publication date: May 21, 2015
    Inventors: David A. Sullivan, Juan Ding, Yang Liu, Wendy Kam
  • Publication number: 20150141357
    Abstract: The present invention relates to methods of inhibiting shikimate pathway, comprising administering to a subject a pharmaceutically acceptable composition comprising a compound having a formula: or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: January 10, 2014
    Publication date: May 21, 2015
    Applicant: NATIONAL TSING HUA UNIVERSITY
    Inventors: Wen-Ching Wang, Shih-Ching Chou, Ming-Hua Hsu
  • Publication number: 20150126466
    Abstract: The invention relates to the field of veterinary science and medicine and can be used for the prophylaxis and treatment of bacterial infections. The aim of the present invention is to design a preparation based on azithromycin in the form of a solution, having a wide spectrum of antimicrobial activity, and in the form of an injection solution ready for use not only for introduction intravenously, but also for intramuscular, subcutaneous, intrauterine and intracisternal introduction. The antibacterial pharmaceutical composition comprises azithromycin, solvents and/or cosolvents, a preservative, and an antioxidant.
    Type: Application
    Filed: June 6, 2013
    Publication date: May 7, 2015
    Inventors: Boris Viktorovich Violin, Sergey Vyacheslavovich Semenov, Dmitriy Vladimirovich Pristenskiy, Aleksandr Andreevich Aniskov
  • Patent number: 9018158
    Abstract: The invention provides a method of overcoming resistance to at least one antibiotic in a multidrug resistant bacterium, said method comprising contacting said bacterium with an alginate oligomer together with the antibiotic. The multidrug resistant bacterium may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use together with at least one antibiotic in treating a subject infected, suspected to be infected, or at risk of infection, with a multidrug resistant bacterium to overcome resistance to the antibiotic in said multidrug resistant bacterium. In another aspect the method can be used to combat contamination of a site with multidrug resistant bacteria, e.g. for disinfection and cleaning purposes.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: April 28, 2015
    Assignee: Algipharma AS
    Inventors: Edvar Onsoyen, Rolf Myrvold, Arne Dessen, David Thomas, Timothy Rutland Walsh
  • Publication number: 20150110767
    Abstract: Methods of treating, reducing, or preventing lung infections or lung inflammation include identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Treatment of cystic fibrosis lung infections, COPD lung infections, inflammation of the lungs in these patient populations, and lung scarring in these patient populations is also described.
    Type: Application
    Filed: October 16, 2014
    Publication date: April 23, 2015
    Applicant: BRIGHAM YOUNG UNIVERSITY
    Inventors: PAUL B. SAVAGE, CARL A. GENBERG, MICHAEL D. TRIPLETT
  • Publication number: 20150111845
    Abstract: Described herein are macrolide and ketolide antibiotics and pharmaceutical compositions, methods, and uses thereof for treating gastrointestinal diseases.
    Type: Application
    Filed: June 19, 2014
    Publication date: April 23, 2015
    Inventor: Prabhavathi FERNANDES